UFP Technologies, Inc. is a contract development and manufacturing organization specializing in single-use and single-patient medical devices. The company serves as an outsourcing partner to major medical device manufacturers, providing custom-engineered components and packaging for applications in minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants. Its product portfolio includes protective drapes for robotic surgery, advanced wound care materials, disposables for surgical and endoscopic procedures, packaging for medical devices, components for cardiac implants, and dispenser coils for catheters. UFP Technologies operates in the medical, biopharma, and diagnostics sectors, utilizing manufacturing processes such as thermoforming, radio frequency welding, and micro-molding. The company was incorporated in 1993 and acquired CI Medical to expand its medical device printing capabilities. It maintains manufacturing facilities that are FDA registered and ISO 13485 certified, supporting customers who require compliance with regulatory standards for medical devices.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Instruments & Supplies Homepage ufpt.com
Sector Healthcare IR page ufpt.com/investors
Tags
contract manufacturing, medical devices, single-use devices, wound care, orthopedics, minimally invasive surgery, infection control, biopharma, medical packaging, thermoforming, foam processing, CI Medical
Press page ufpt.com/news

Metrics

Valuation  
Market cap $ 2.299B
Market cap (USD) $ 2.299B
P/E 30.35
PEG 1.70
P/BV 4.73
P/S 3.54
P/OCF 30.99
P/FCF 29.11
Dividend yield —
Turnover / mcap —
Returns  
ROE 17.8%
ROI 12.2%
ROIC 13.7%
Profit margin 11.3%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 17.8%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 19.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 22
Quality score 27.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 602.797M 504.421M 400.072M 353.792M 206.32M 179.373M 198.381M 190.455M 147.843M 146.132M 138.85M 139.307M 139.223M 130.962M 127.244M 120.766M 99.231M 110.032M 93.595M 93.749M 83.962M 68.624M 60.902M 61.189M 61.574M 74.492M
Net profit 68.313M 58.981M 44.924M 41.789M 15.886M 13.369M 19.75M 14.311M 9.21M 7.97M 7.593M 7.559M 11.276M 10.895M 10.784M 9.408M 5.982M 5.116M 4.159M 2.515M 659.091K 871.261K -1.516M -233.795K -3.043M 1.081M
Free cash flow 78.979M 56.937M 30.844M 3.964M 8.898M 20.669M 25.451M 15.892M 7.087M 2.1M -3.223M -2.31M 10.276M 4.168M 7.975M 8.542M 8.832M 3.922M 8.046M 10.578M -101.596K -708.113K -491.35K 1.295M -208.936K 1.117M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 222.03 244.51 172.04 117.89 70.26 46.6 49.61 30.04 27.8 25.45 23.82 24.58 25.22 17.92 14.78 12.2 5.84 4.08 4.91 4.45 — — — — — —
Price performance 12m -0.09 0.42 0.46 0.68 0.51 -0.06 0.65 0.08 0.09 0.07 -0.03 -0.03 0.41 0.21 0.21 1.09 0.43 -0.17 0.1 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 21.2M 21.4M 28.3M 28.6M 26.4M 39.4M 55.1M 64.4M 84.7M 82.9M
↳ YoY growth +21.6% +0.6% +32.5% +1.2% -7.7% +49.0% +39.9% +16.9% +31.4% -2.1%
↳ 5y CAGR +6.4% +3.7% +10.7% +11.7% +8.6% +13.1% +20.9% +17.9% +24.2% +25.7%
Borrowings, current (USD) 856,000 — 2.86M — 0.00 4M 4M 4M 12.5M 12.5M
Borrowings, non-current (USD) — — 22.3M — 0.00 71M 51M 28M 177M 123M
Lease liabilities (USD) — — 0.00 3.09M 2.21M 9.36M 13.2M 13.9M 16.7M 19M
Cash and deposits (USD) 31.4M 38M 3.24M 3.74M 24.2M 11.1M 4.45M 5.26M 13.5M 20.3M
Intangible assets (USD) 318,000 — 22.2M 21M 19.7M 67.6M 68.4M 64.1M 144M 141M
Right-of-use assets (USD) — — 4M 3.03M 2.05M 9.05M — 13.4M 16.1M 18.8M
Net debt (borrowings + leases - cash) (USD) -30.5M — 21.9M — -22M 73.2M 63.7M 40.6M 193M 134M
Cash flow detail
Operating cash flow (USD) 9.39M 17.5M 21.3M 31.2M 25M 14.3M 17.7M 41.3M 66.6M 91.9M
Purchases of property, plant and equipment (USD) -7.29M -10.4M -5.43M -5.78M -4.37M -5.4M -13.8M -10.5M -9.66M —
Change in receivables (cash effect) (USD) -3.77M -132,000 -2.56M -327,000 2.22M -7.75M -16.9M -9.12M 1.22M 5.34M
Change in inventories (cash effect) (USD) 51,000 1.29M -2.3M 1.3M -366,000 -4.5M -19.6M -16.6M -4.69M 3.9M
Change in payables (cash effect) (USD) -596,000 93,000 1.11M -2.47M -681,000 102,000 9.13M 1.55M -1.14M -1.09M
Interest paid (cash effect) (USD) -66,000 -47,000 -1.3M -664,000 -71,000 -53,000 -2.72M -3.54M -7.89M -9.86M
Income taxes paid (cash effect) (USD) -3.56M -3.88M -3.46M -1.26M -2.48M -5.91M -13.2M -10.6M -12.8M -3.56M
Share-based compensation (USD) 1.06M 1.07M 1.21M 1.59M 1.81M 2.43M 3.21M 4.64M 6.84M 8.85M
Operating cash flow before change in receivables (USD) 13.2M 17.6M 23.9M 31.6M 22.8M 22M 34.6M 50.5M 65.4M 86.6M
Free cash flow (OCF - PPE - intangibles) (USD) 2.1M 7.09M 15.9M 25.5M 20.7M 8.9M 3.96M 30.8M 56.9M —
Income detail
Research and development expense (USD) 1.3M 1.1M 10.5M 9.5M 8.2M 8.5M 9.3M 7.2M 10.4M 8.6M
↳ 5y CAGR +1.6% -3.3% +54.3% +51.3% +42.4% +45.6% +53.3% -7.3% +1.8% +1.0%
Total comprehensive income (USD) — — — — 13.4M 15.9M 41.2M 45.8M 54.5M 76.2M
Comprehensive income to owners (USD) — — — — 13.4M 15.9M 41.2M 45.8M 54.5M 76.2M
Provision for credit losses (USD) 126,000 116,000 -50,000 -52,000 13,000 179,000 293,000 15,000 213,000 31,000
Credit cost ratio (credit losses / average receivables) (%) 0.7% 0.5% 0.2% 0.2% 0.0% 0.5% 0.6% 0.0% 0.3% 0.0%
Reported Mar 16, 2018 Mar 16, 2018 Mar 13, 2020 Mar 13, 2020 Mar 16, 2023 Mar 16, 2023 Mar 16, 2023 Aug 9, 2024 Mar 3, 2025 Feb 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

UFP Technologies Announces Strong Q3 Results Bull 4 Bear 0 Results

Newburyport, Mass., November 3, 2026. UFP Technologies, Inc. (Nasdaq: UFPT), a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and other highly engineered custom products, today reported net income of $20.6 million for its third quarter ended September 30, 2026, 25.8% higher than net income of $16.4 million for the third quarter of 2025. Net sales for the quarter ended September 30, 2026 were $172.4 million, 11.6% higher than 2025 third quarter sales of $154.6 million. Generally accepted accounting principles ("GAAP") and adjusted earnings per diluted common share outstanding ("EPS") for the quarter ended September 30, 2026 were $2.64 and $2.88, respectively. Net income for the nine-month period ended September 30, 2026 was $59.0 million, 16.2% higher than net income of $50.7 million for the same period in 2025. Net sales for the nine-month period ended September 30, 2026 were $500.6 million, compared to sales of $453.9 million in the same period of 2025. GAAP and adjusted EPS for the nine-month period ended September 30, 2026 were $7.56 and $8.28, respectively.

Scroll to first section Down Arrow

Newburyport, MA, October 29, 2026 – UFP Technologies, Inc. (Nasdaq: UFPT), a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and other highly engineered custom products, today announced that the Company plans to report results for the third quarter on Tuesday, November 3rd, after the close of the stock market. The Company will hold a conference call to discuss the results on the following day, November 4th, at 8:30 AM Eastern time. 

**Conference Call Information:
**Date: Wednesday, November 4, 2026
Time: 8:30 AM Eastern Time

Participants may join the call using the following dial-in numbers:

  • USA/Canada: Toll-Free: 1-412-206-6478
  • International: 1-833-890-4010

A live webcast of the conference call and accompanying materials will be available here .

A replay of the webcast will be accessible following the event on the Company’s Investor Relations website at https://ufpt.com/investors/ .

**About UFP Technologies, Inc.
**UFP Technologies is a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and other highly engineered custom products. The Company’s single-use and single-patient devices and components are used across a wide range of medical products in segments including robotic assisted surgery, patient beds, infection control, cardiovascular, orthopedics and spine and wound car.

**Investor Contact:
**Jeff Elliott
Three Part Advisors, LLC
214-966-9014

**UFP Technologies Contact:
**Ron Lataille, CFO
978-234-0926
[email protected]

Newburyport, MA, September 9, 2026 — UFP Technologies, Inc. (Nasdaq: UFPT), a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and other highly engineered custom products, today announced the acquisition of CI Medical

, further expanding the Company’s capabilities and complementing its existing breadth of material and technical expertise.

Founded in 1985 and headquartered in Norton, Massachusetts, CI Medical is a market leader in pad printing hard-to-stick materials for the medical device industry. The Company is ISO 9001:2015 certified and its team members are experts in precision printing on some of the industry’s most challenging substrates.

“CI Medical is a fantastic strategic fit for us,” said Mitch Rock, President and CEO of UFP Technologies. “They are a trusted development partner and a strong cultural fit, with a seasoned team that has deep expertise in medical manufacturing. Like us, they pride themselves on being true partners from concept to scale.”

Prompts

UFP Technologies, Inc. (ticker UFPT), listed in United States.

ETFs Holding UFP Technologies, Inc.

ETF Weight in ETF Shares Market value As of
TMFS 4.16% 8,129 $ 2.422M Aug 31, 2026
CSMD 2.63% 46,829 $ 11.931M Jul 31, 2026
SMCO 1.64% 8,021 $ 2.395M Nov 17, 2026
NBSM 1.15% 4,427 $ 1.319M Aug 31, 2026
SSMG 0.88% 110 $ 28.026K Jul 31, 2026
RUSC 0.22% 645 $ 171.009K Jun 30, 2026
PSC 0.18% 15,566 $ 4.127M Jun 30, 2026
IVSS 0.17% 170 $ 45.072K Jun 30, 2026
AVSC 0.15% 15,697 $ 4.686M Nov 16, 2026
RESM 0.09% 13 $ 3,446.69 Jun 30, 2026
RILA 0.06% 92 $ 23.44K Jul 31, 2026
DFAS 0.05% 57,295 $ 17.527M Nov 12, 2026
DXUV 0.02% 3,726 $ 1.14M Nov 12, 2026
MSSM 0.01% 279 $ 83.128K Aug 31, 2026
DFAC 0.01% 32,160 $ 9.838M Nov 12, 2026
DFUV 0.01% 4,811 $ 1.472M Nov 12, 2026
DCOR 0.01% 10,513 $ 3.216M Nov 12, 2026
DFUS 0.00% 2,899 $ 886.833K Nov 12, 2026
DFAU 0.00% 1,665 $ 509.34K Nov 12, 2026
EBI 0.00% 18 $ 5,363.10 Aug 31, 2026
AVUS 0.00% 1,361 $ 406.313K Nov 16, 2026
AVSU 0.00% 42 $ 12.539K Nov 16, 2026